Late Stage Chronic Kidney Disease Drugs Market: High Prevalence of Diseases Leading to Chronic Kidney Diseases
The late stage chronic kidney disease drugs market was valued at US$ 4,680.0 million in 2019 and is projected to reach US$ 11,096.9 million by 2027; it is expected to grow at a CAGR of 11.6% from 2020 to 2027.
Late-stage renal disease, also called end-stage kidney disease, occurs when chronic kidney disease (the gradual loss of kidney function) reaches an advanced state. In end-stage renal disease, kidneys are no longer able to work as they should to meet the body's needs. At this advanced stage, the kidney loses all its ability to function effectively, and eventually dialysis or a kidney transplant is needed to save the life. High prevalence of diseases leading to chronic kidney diseases and favorable reimbursement policy for the late stage chronic kidney disease drugs are the major factor propelling the market growth. However, delay in the diagnosis of chronic kidney disease is expected to hamper the growth of the market up to certain extent during the forecast period.
Request for sample at: https://www.theinsightpartners.com/sample/TIPRE00013768/
Key Findings from The late stage chronic kidney disease drugs Market
Based on product type, the late stage chronic kidney disease drugs market is segmented into calcimimetics, vitamin D, potassium binders, calcium-based phosphate binders, and others. The calcimimetics segment held the highest share of the late stage chronic kidney disease drugs market in 2019 and is estimated to register the highest CAGR of 12.1% in the market during the forecast period.
Calcimimetics are commonly used in patients on dialysis to treat secondary hyperparathyroidism. Mineral and bone disorders (MBD) are the common complications of chronic kidney disease (CKD), which are significant risk factors in mortality in CKD patients. Cinacalcet, the only available calcimimetic, is a useful therapeutic in CKD-MBD. Various clinical trials with cinacalcet in hemodialysis patients with SHPT have shown a reduction in parathyroid hormone, phosphate (P), calcium (Ca), and Ca x P product levels more tremendous success in reaching therapeutic goals as per the recommendations of international guidelines.
Additionally, some studies have shown that cinacalcet may improve other aspects of CKD-MBD, and reduces the risk of parathyroidectomy and vascular calcification, among others. Secondary hyperparathyroidism (SHPT) is a highly prevalent and crucial complication in patients with chronic kidney disease (CKD). Calcimimetic agents may help control SHPT and achieve the though mineral metabolism targets in patients with late stage chronic kidney disease.
Based on indication, the late stage chronic kidney disease drugs market is segmented into late stage chronic kidney disease induced hyperparathyroidism, late stage chronic kidney disease induced hyperphosphatemia, and late stage chronic kidney disease induced hyperkalemia.
AbbVie Inc.; Amgen; AstraZeneca; Sanofi; Kyowa Kirin Co., Ltd.; Takeda Pharmaceutical Company Limited; Astellas Pharma Inc.; Bayer AG; Vifor Pharma Management Ltd.; and Akebia Drugs, Inc. are among the prominent players operating in the late stage chronic kidney disease drugs market.
High Prevalence of Diseases Leading to Chronic Kidney Diseases
Chronic kidney disease (CKD) is a common and life-threatening condition that affects 1 in 10 people worldwide. It affects more than 26 million Americans and millions more worldwide. High blood pressure and diabetes were the two major causes in 75% of kidney failure cases between 2015 and 2017. 47% of new end-stage kidney disease (ESKD) patients had a primary diagnosis of diabetes, while 29% of new end-stage kidney disease patients had a primary diagnosis of hypertension. Moreover, according to Bayer's press release, about 29 million people in the US have type 2 diabetes, and 40% will develop CKD in the coming year.
According to the CDC, 1 in 3 adults with diabetes and 1 in 5 adults with high blood pressure might have chronic kidney disease. In 2015, 30.3 million people in the US had diabetes as per the American Diabetes Association (ADA). According to the CDC, in 2014, around 118,000 people in the US have started the treatment for end-stage renal disease, and the number of people for treatment is expected to increase as more people become aware of this condition. Moreover, the CDC states that around 96% of the people with kidney damage are not aware of having chronic kidney disease, which indicates the underlying market prospective in the late stage of chronic kidney disease drugs. These factors are expected to enhance market growth during the forecast period.
Introduction of New Preclinical Models to Improve Target Validation and Understand Disease Development
Manufactures are in a stronger position than ever before to look for targets and treatments and now they have a deeper molecular understanding of CKD. Various manufacturers are investing in the development of sophisticated models that mimic the human kidney accurately than has ever previously been possible. It is impossible to virtually imitate the functions of kidney in classical in vitro systems, while in vivo models; it is intensive to produce, and not always adaptable to human systems. 3D bioprinting and organs-on-chips are the new model systems that the manufacturers in the market are embedding into their research pipeline to bridge this gap. With these groundbreaking techniques, they can test compound behavior and hope to understand disease mechanisms in a subtle way.
Organs-on-Chip technology provides environments that emulate major aspects of the real kidney physiology; including fluidic channels that are lined with living cells in the accurate structural design. The flow represents the flow of blood carrying nutrients, takes away waste products, and also creates mechanical forces, all critical factors for the functioning of the kidney.
Place an Order Now: https://www.theinsightpartners.com/buy/TIPRE00013768/
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.
Contact Person: Sameer Joshi